Foolproof Stock: Theravance Biopharma, Inc. (NASDAQ: TBPH)
Theravance Biopharma, Inc. (NASDAQ: TBPH) spotted trading -17.81% off 52-week high price. On the other end, the stock has been noted 55.01% away from the low price over the last 52-weeks. The stock changed 3.57% to recent value of $23.53. The stock transacted 819771 shares during most recent day however it has an average volume of 277.3K shares. The company has 54.76M of outstanding shares and 39.28M shares were floated in the market.
Theravance Biopharma, Inc (TBPH) recently stated financial results for the third quarter ended September 30, 2019. Revenue for the third quarter of 2019 was $12.4M. Third quarter operating loss was $65.2M or $52.2M not including share-based compensation expense. Cash, cash equivalents, marketable securities, and restricted cash totaled $352.9M as of September 30, 2019.
Third Quarter Financial Results
Total revenue for the third quarter of 2019 was $12.4M contrast to $12.8M in the same period in 2018. The decrease was primarily Because of a decrease in product sales which resulted from the sale of VIBATIV® to Cumberland Pharmaceuticals in late-2018, mostly offset by revenue from the Mylan alliance contract for YUPELRI®.
Research and Development (R&D) Expenses
R&D expenses for the third quarter of 2019 were $52.0M, contrast to $52.7M in the same period in 2018. The decrease was primarily Because of lower employee-related costs associated with the reduction in force reported in the first quarter of 2019, partially offset by a raise in external expenses related to the progression of our key programs. Third quarter R&D expenses included non-cash share-based compensation of $6.5M.
Selling, General and Administrative (SG&A) Expenses
SG&A expenses for the third quarter of 2019 were $25.6M, contrast to $21.9M in the same period in 2018. The increase was primarily Because of higher external expenses and share-based compensation, partially offset by lower employee-related costs associated with the reduction in force reported in the first quarter of 2019. Third quarter SG&A expenses included non-cash share-based compensation of $6.6M.
Cash, Cash Equivalents and Marketable Securities
Cash, cash equivalents, marketable securities, and restricted cash, totaled $352.9M as of September 30, 2019.
2019 Financial Guidance
The Company has reduced its 2019 full year operating loss guidance to a range of $200.0M to $210.0M, not including non-cash share-based compensation. The reduction in operating loss guidance is primarily Because of additional licensing revenue recognized in the second quarter of 2019 associated with the upfront payment received from Mylan for YUPELRI development and commercialization rights in China. Operating loss guidance does not include royalty income for TRELEGY ELLIPTA which the Company recognizes as non-operating income. Our future financial guidance could be influenced by factors including, but not limited to our share of U.S. profits and losses related to the commercialization of YUPELRI, potential future business development collaborations as well as the timing and cost of clinical studies associated with its key programs.
The price moved ahead of 14.81% from the mean of 20 days, 27.61% from mean of 50 days SMA and performed 17.52% from mean of 200 days price. Company’s performance for the week was 13.56%, 35.85% for month and YTD performance remained -8.05%.